Prelude Therapeutics Inc Annual Share-based Payment Arrangement, Expense in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Prelude Therapeutics Inc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2019 to 2023.
  • Prelude Therapeutics Inc Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $5.93M, a 11.8% decline year-over-year.
  • Prelude Therapeutics Inc Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $23.5M, a 8.09% decline year-over-year.
  • Prelude Therapeutics Inc annual Share-based Payment Arrangement, Expense for 2023 was $25.6M, a 1.88% increase from 2022.
  • Prelude Therapeutics Inc annual Share-based Payment Arrangement, Expense for 2022 was $25.1M, a 20.1% increase from 2021.
  • Prelude Therapeutics Inc annual Share-based Payment Arrangement, Expense for 2021 was $20.9M, a 275% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $25.6M +$472K +1.88% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-15
2022 $25.1M +$4.21M +20.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-15
2021 $20.9M +$15.3M +275% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-15
2020 $5.58M +$4.74M +560% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-17
2019 $846K Jan 1, 2019 Dec 31, 2019 10-K 2021-03-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.